ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background5-Aminolevulinic acid photodynamic therapy (ALA-PDT) is a promising treatment for glioblastoma multiforme (GBM), the most malignant form of brain cancer. However, challenges persist. The heterogeneous and invasive nature of GBM frequently results in hypoxic regions within the tumor and its periphery, where the efficacy of PDT may be diminished. Consequently, it is imperative to explore combination treatments that enhance PDT-induced cell death. Resveratrol (Res) is a natural phenolic compound recognized for its anti-inflammatory and anti-tumor properties against glioblastoma cells. Given these considerations, the study employed sublethal-dose ALA-PDT to simulate the reduced efficacy of ALA-PDT commonly observed in GBM and explored the effects of combining Res with sublethal-dose ALA-PDT on glioblastoma cells in vitro.
methodsHuman glioblastoma U251 and U87 cells were treated with Res and/or sublethal-dose ALA-PDT. Cell viability, migration inhibition, and apoptosis were assessed using the CCK-8 assay, colony-forming assay, scratch assay, Calcein-AM/PI, and TUNEL staining. Western blotting was performed to detect the expression levels of proteins involved in the ERK1/2 and mTOR signaling pathways and autophagy.
resultsRes inhibited the viability of U251 and U87 cells in a dose- and incubation time-dependent manner. Compared to single treatments, the combination of sublethal-dose ALA-PDT and Res reduced cell viability and migration and induced apoptosis. This combined treatment suppressed the ERK1/2 and mTOR signaling pathways. Additionally, Res enhanced ALA-PDT-induced autophagy-dependent cell death, as autophagy inhibitors partially reversed the decrease in cell viability resulting from the combined treatment.
conclusionThis study demonstrates that the combination of Res and ALA-PDT enhances the inhibition of glioblastoma cell growth compared to the single treatments. The combined therapy can induce apoptosis and autophagy in GBM cells by suppressing the ERK1/2 and mTOR signaling pathways, providing a potential new treatment for GBM. However, in vivo validation and clinical trials are essential for fully evaluating the potential of this mechanism regarding translation into clinical application.
Indexed as
Identifiers
41801670What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.